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Abstract
Background: The European System for Cardiac Operative Risk Evaluation (EuroSCORE) is a
widely used risk assessment tool in patients with severe aortic stenosis to determine operability
and to select patients for alternative therapies such as transcatheter aortic valve implantation. The
objective of this study was to determine the accuracy of the EuroSCORE in predicting mortality
following aortic valve replacement (AVR).
Methods: The logistic EuroSCORE was determined for all consecutive patients that underwent
conventional AVR between 1995 and 2005 at our institution. Provincial Vital Statistics were used
to determine all-cause mortality. The accuracy of the prognostic risk prediction provided by logistic
EuroSCORE was assessed by comparing observed and expected operative mortality.
Results: During the study period, a total of 1,421 patients underwent AVR including 237 patients
(16.7%) that had a logistic EuroSCORE > 20. Among these patients, the mean predicted operative
mortality was 38.7% (SD = 18.1). The actual mortality of these patients was significantly lower than
that predicted by EuroSCORE (11.4% vs. 38.7%, observed/expected ratio 0.29, 95% CI 0.15–0.52,
P < 0.05). The EuroSCORE overestimated mortality within all strata of predicted risk. Although
medium-term mortality is significantly higher among patients with EuroSCORE > 20 (log rank P =
0.0001), approximately 60% are alive at five years.
Conclusion: Actual operative mortality in patients undergoing AVR is significantly lower than that
predicted by the logistic EuroSCORE. Additionally, medium-term survival following AVR is
acceptable in high-risk patients with EuroSCORE > 20. More accurate risk prediction models are
needed for risk-stratifying patients with severe aortic stenosis.
Introduction
Aortic valve replacement (AVR) is established therapy for
the treatment of severe, symptomatic aortic stenosis (AS)
and has been shown to relieve symptoms and signifi-
cantly improve survival [1-4]. Conventional AVR involves
median sternotomy and the institution of cardiopulmo-
nary bypass, excision of the stenotic native valve, and
replacement with a biologic or mechanical prosthesis.
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Recently, catheter-based transfemoral and transapical
approaches to aortic valve implantation have been devel-
oped for patients with severe AS that are thought to be
inoperable because of advanced age or significant comor-
bidities, with acceptable early results [5-13].
In these studies, patient selection for transcatheter therapy
was determined largely on the basis of the European Sys-
tem for Cardiac Operative Risk Evaluation (EuroSCORE).
The EuroSCORE is a surgical risk scoring system devel-
oped in 1999 from a multinational European database
[14]. The model provides an estimate of a patient's antic-
ipated 30-day mortality according to the patient's demo-
graphic characteristics, cardiovascular and non-
cardiovasculr risk factors, and procedural variables. Its
predictive accuracy has previously been validated in a vari-
ety of clinical settings [15-17]. However, concerns have
been raised about the EuroSCORE's ability to accurately
predict outcomes of patients at the extremes of risk and
patients undergoing valve surgery [18-22].
In order to assess the accuracy of the prognostic risk pre-
diction provided by EuroSCORE, we examined the opera-
tive and long-term mortality of a contemporary, real-
world cohort of patients with a pre-procedural logistic
EuroSCORE > 20 (which represents a predicted operative
mortality risk of 20%) that have undergone conventional
AVR.
Methods
Study design and patients
A retrospective cohort design was used. All consecutive
adult patients who underwent conventional AVR between
March 1995 and September 2005 at our institution were
identified. Indications for AVR were based on clinical
symptoms and disease severity and were consistent with
current consensus guidelines [4]. The selection of patients
for AVR is the result of a weekly round-table peer-review
process involving cardiologists, cardiac surgeons, and car-
diac radiologists, during which patients with severe symp-
tomatic AS are discussed and the timing of operation
established according to a previously published algorithm
[23].
Baseline patient demographics, cardiovascular and non-
cardiovascular comorbid illnesses, as well as data on intra-
operative variables and postoperative in-hospital events
were captured in a prospective fashion in our institutional
database. The database is audited annually, has < 5%
missing data fields, and is free of systematic error [24].
Definitions of variables and outcome measures in the
database are consistent with the standards published by
the Society of Thoracic Surgeons [25].
The logistic EuroSCORE was computed for each patient in
the study using the β coefficients of the logistic regression
equation reported for the EuroSCORE [14,26]. The score
thus obtained corresponds exactly to the operative mor-
tality predicted for a given patient, defined as death occur-
ring anytime during the same postoperative hospital stay
of any duration or within 30 days of surgery for patients
discharged to home or to a secondary institution. The dis-
tribution of demographic, clinical, and operative variables
was compared among patients with EuroSCORE ≤ 20 and
those with EuroSCORE > 20. A EuroSCORE cut-off of 20,
representing a predicted operative mortality of 20%, was
chosen a priori to define low- and high-risk patient sub-
groups on the basis of previously published reports evalu-
ating the safety, feasibility, and efficacy of transcatheter
aortic valve implantation in which patients with Euro-
SCORE > 20 were considered to have too high a risk to be
candidates for conventional AVR and were subsequently
referred for catheter-based aortic valve implantation [5-
13,27].
Clinical outcomes
The primary outcome of interest in this study was opera-
tive mortality, defined as death within 30 days of opera-
tion or within the same hospital admission. Because our
institutional database captures in-hospital mortality only,
we linked survivors to discharge to government vital sta-
tistics data to determine 30-day, 1, 3, and 5-year survival.
Survival times were analyzed using Kaplan-Meier method-
ology and log-rank statistics were used to compare sur-
vival curves among patients with logistic EuroSCORE > 20
and those with logistic EuroSCORE ≤ 20 [28].
Other postoperative adverse events examined were:
dependence on a mechanical ventilator for a period
exceeding 24 hours, stroke, the transfusion of banked red
blood cells, new-onset atrial fibrillation, the implantation
of a permanent pacemaker secondary to new, postopera-
tive complete heart block, and length of hospitalization
from the time of operation to discharge. Stroke was
defined as a permanent neurologic deficit occurring after
surgery with an acute change on intracranial computed
tomography or magnetic resonance imaging.
Postoperative delirium and acute, reversible deficits were
not included in the stroke end-point. Individual out-
comes were univariately compared among patients with
logistic EuroSCORE ≤ 20 and those with logistic Euro-
SCORE > 20. The accuracy of the prognostic risk predic-
tion provided by EuroSCORE was assessed by comparing
observed and expected operative mortality. Ninety-five
percent confidence intervals (CI) for the observed-to-
expected ratios (O/E) were generated using Byar's approx-
imation [29].Journal of Cardiothoracic Surgery 2009, 4:32 http://www.cardiothoracicsurgery.org/content/4/1/32
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Statistical analysis
Statistical analysis for the study was performed using Sta-
tistical Analysis System (SAS) software version 8.2 (SAS
Institute, Cary, North Carolina). Continuous variables are
expressed as mean ± 1 standard deviation (SD). Continu-
ous variables were compared using unpaired t-tests or
non-parametric equivalents where appropriate. Propor-
tions were compared using chi-square tests (or Fisher's
exact test where appropriate) and Mantel-Haenszel chi-
square statistics with one degree of freedom were used to
test for trends across ordered categories. Comparisons
were considered statistically significant if the P value was
less than 0.05. All P values were two-sided.
The study protocol was in accordance with the institu-
tional clinical research ethics board and received full eth-
ical approval.
Results
Baseline characteristics
Between 1995 and 2005, 1,421 patients underwent AVR
at our institution. Among these patients, 237 (16.7%) had
a logistic EuroSCORE > 20. Patients with logistic Euro-
SCORE > 20 were more likely to have a number of high-
risk features such as advanced age, depressed systolic func-
tion of the left ventricle, and chronic renal insufficiency,
although were not different from patients with logistic
EuroSCORE ≤ 20 with respect to gender, or the prevalence
of diabetes mellitus, hypertension, hyperlipidemia, and
active or former cigarette smoking (Table 1). In addition,
the acuity of operation, the type of prosthesis implanted,
the need for concomitant revascularization or thoracic
aortic repair, and operative durations also differed among
the two groups (Table 2).
Early outcomes
The overall operative mortality, defined as death occur-
ring anytime during the same postoperative hospital stay
or within 30 days of surgery for patients discharged to
home or to a secondary institution, for the entire cohort
of patients was 4.6% (n = 66). The operative mortality was
significantly higher among patients with logistic Euro-
SCORE > 20 compared to those with EuroSCORE ≤ 20
(11.4% vs. 3.2%, respectively, P < 0.0001). Of the pre-
specified in-hospital adverse events following surgery
examined, only the incidence of new-onset postoperative
atrial fibrillation was similar between the two groups
(Table 3).
Table 1: Baseline characteristics of patients with EuroSCORE > 20 compared to those with EuroSCORE ≤ 20
Variable, % unless otherwise indicated EuroSCORE > 20,
n = 237
EuroSCORE ≤ 20,
n = 1,184
Demographic data
Age
<60 yrs 11.4 24.7
60–69 yrs 13.9 25.4
70–79 yrs 42.6 37.3
≥ 80 yrs 32 12.6
Age, mean yrs ± SD 73.2 ± 12.4 66.7 ± 12.8
Female 35.0 33.8
Cardiovascular risk factors/diseases
Current or former cigarette smoking 57.0 61.5
Body mass index, mean kg/m2 ± SD 26.6 ± 4.6 28.2 ± 5.3
Active endocarditis 8.0 1.1
Diabetes mellitus 22.8 21.5
Hypertension 59.9 53.3
Extracardiac arteriopathy 56.5 18.6
Pulmonary hypertension 31.2 5.2
Previous cardiac surgery 30.4 7.9
Left ventricular ejection fraction
>0.50 37.6 80.4
0.30–0.50 35.4 16.4
<0.30 27.0 3.2
Unstable angina 14.4 0.8
MI within 21 days of surgery 13.1 2.6
Hyperlipidemia 48.5 49.1
Medical comorbidities
Hemoglobin, mean g/dL ± SD 12.2 ± 1.9 13.5 ± 1.7
Serum creatinine > 200 μmol/L 15.2 1.9
Chronic lung disease 33.3 15.0
MI = myocardial infarction; SD = standard deviation.Journal of Cardiothoracic Surgery 2009, 4:32 http://www.cardiothoracicsurgery.org/content/4/1/32
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Among the subgroup of patients with logistic EuroSCORE
> 20, the mean predicted operative mortality by Euro-
SCORE was 38.7% ± 18.1%. The actual mortality of these
patients was significantly lower than that predicted by
EuroSCORE (11.4% vs. 38.7%, O/E 0.29, 95% CI 0.15 –
0.52, P < 0.05) (Figure 1). In the lower-risk subgroup of
patients with logistic EuroSCORE ≤ 20, mean predicted
operative mortality was 7.1% ± 4.8%. The observed mor-
tality in these patients was 3.2%, although this difference
was not statistically significant (O/E 0.47, 95% CI 0.10 –
1.30, P > 0.05). In addition, the EuroSCORE overesti-
mated operative mortality within all strata of predicted
risk, the magnitude of the discrepancy getting larger with
increasing risk (Figure 2).
A simple linear regression model of actual mortality was
fit as a function of EuroSCORE as the independent varia-
ble and compared to the predicted mortality given by
EuroSCORE (Figure 3). Although there is a statistically sig-
nificant association between EuroSCORE and operative
mortality (r2 = 0.95) such that increasing EuroSCORE is
associated with increasing mortality, the two curves are
widely divergent and the difference between them
increases with increasing predicted risk.
Late outcomes
Patients were linked to vital statistics databases to deter-
mine mortality from any cause. The Kaplan-Meier free-
dom from all-cause mortality was significantly lower for
patients with logistic EuroSCORE > 20 compared to those
with logistic EuroSCORE ≤ 20 at 1, 3, and 5 years: 80.9%
vs. 93.5%, 68.5% vs. 87.9%, and 56.2% vs. 82.1%, respec-
tively (log-rank P = 0.0001) (Figure 4).
Discussion
The purpose of this study was to determine the early and
medium-term outcomes of a contemporary cohort of
patients with severe symptomatic AS undergoing AVR and
to evaluate the accuracy of the EuroSCORE in predicting
operative mortality. We have shown that in a tertiary care
surgical practice in Canada a significant proportion of
patients requiring AVR for severe symptomatic AS
Table 2: Operative characteristics of patients with EuroSCORE > 20 compared to those with EuroSCORE ≤ 20
Variable, % unless otherwise indicated EuroSCORE > 20,
n = 237
EuroSCORE ≤ 20,
n = 1,184
Critical preoperative state* 24.5 1.0
Emergency surgery 10.1 0.9
Concomitant thoracic aortic surgery 16.5 5.7
Concomitant CABG 58.7 42.2
Type of prosthesis
Bioprosthesis (tissue valve)
Mechanical valve
Homograft
84.0
13.5
2.5
81.7
17.6
0.8
Cardiopulmonary bypass time, mean min ± SD 178.5 ± 64.4 148.8 ± 51.8
Aortic clamp time, mean min ± SD 122.8 ± 47.0 106.7 ± 37.8
Prosthetic valve indexed EOA§<0.75 cm2/m2 4.7 10.4
*Includes: resuscitated cardiac arrest, dependence on mechanical ventilator, and cardiogenic shock requiring inotropic support and/or intra-aortic 
balloon counterpulsation.
§Effective orifice area was computed for each implanted valve type and size according to the measurements published by valve manufacturers and/
or independent adjudicators and was indexed on patient body surface area.
CABG = coronary artery bypass graft surgery; EOA = effective orifice area; SD = standard deviation.
Table 3: Early postoperative outcomes of patients with EuroSCORE > 20 compared to those with EuroSCORE ≤ 20
Outcome, % EuroSCORE > 20,
n = 237
EuroSCORE ≤ 20,
n = 1,184
P
Mortality (in-hospital or within 30 days of surgery) 11.4 3.2 <0.0001
In-hospital events
Ventilation > 24 hours 27.9 9.3 <0.0001
Length of stay > 9 days 59.1 28.1 <0.0001
Stroke 5.1 2.3 0.02
Atrial fibrillation (new onset) 31.7 28.4 0.31
Erythrocyte transfusion 73.0 34.5 <0.0001
Permanent pacemaker implantation 10.1 5.4 0.01Journal of Cardiothoracic Surgery 2009, 4:32 http://www.cardiothoracicsurgery.org/content/4/1/32
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(16.7%) were found to have a high predicted operative
mortality based on logistic EuroSCORE. We have arbitrar-
ily chosen a logistic EuroSCORE > 20, which corresponds
to a predicted in-hospital or 30-day mortality > 20%, as
our cutoff of high risk based on published reports that
have suggested that such patients may be considered
inoperable and potentially eligible for alternative cathe-
ter-based therapy. Among the patients in our cohort with
logistic EuroSCORE > 20, the mean operative mortality
predicted by EuroSCORE was 38.7%. However, the actual
mortality observed was 11.4%, significantly lower than
that predicted by EuroSCORE (P < 0.05). In addition, the
EuroSCORE appeared to overestimate operative mortality
within all strata of predicted risk. The discrepancy
Predicted and observed mean operative mortality among  patients with EuroSCORE > 20 compared to those with  EuroSCORE ≤ 20 Figure 1
Predicted and observed mean operative mortality 
among patients with EuroSCORE > 20 compared to 
those with EuroSCORE ≤ 20. Among high-risk patients 
with logistic EuroSCORE > 20, the actual operative mortality 
following AVR was significantly lower than that predicted by 
EuroSCORE (11.4% vs. 38.7%, respectively, O/E 0.29, 95% CI 
0.15–0.52, P < 0.05).
Predicted and observed mean operative mortality within all  subgroups of EuroSCORE Figure 2
Predicted and observed mean operative mortality 
within all subgroups of EuroSCORE. The EuroSCORE 
overestimated operative mortality in all categories of risk.
Simple linear regression model of observed mortality as a  function of logistic EuroSCORE compared with predicted  mortality Figure 3
Simple linear regression model of observed mortality 
as a function of logistic EuroSCORE compared with 
predicted mortality. There is a statistically significant asso-
ciation between logistic EuroSCORE and actual operative 
mortality (r2 = 0.95), although the empiric model is different 
from the theoretical model provided by EuroSCORE.
Five-year freedom from all-cause mortality Figure 4
Five-year freedom from all-cause mortality. The Kap-
lan-Meier survival among patients with logistic EuroSCORE > 
20 is significantly worse compared to those with logistic 
EuroSCORE ≤ 20.Journal of Cardiothoracic Surgery 2009, 4:32 http://www.cardiothoracicsurgery.org/content/4/1/32
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between observed and expected mortality widened as pre-
operative risk determined by EuroSCORE increased.
Although long-term mortality from any cause is signifi-
cantly higher among patients with EuroSCORE > 20 (log
rank P = 0.0001), approximately 60% are alive at five
years after operation. Similar findings were recently
reported by Brown et al [22]. However, unlike our study,
no data are given on longitudinal outcomes.
The EuroSCORE predictive model for cardiac surgery has
been extensively studied and found to accurately predict
outcomes in a variety of jurisdictions and clinical practices
[14-16,30]. The initial additive EuroSCORE model was
simple and reproducible and it could readily be used at
the patient's bedside for rapid assessment of operative
risk. However, what it gained in parsimony, interpretabil-
ity, and ease of use, it lost in accuracy as it was found to
have a tendency to over-predict mortality in low-risk
patients and under-predict mortality in high-risk patients
[31]. The later-appearing logistic EuroSCORE, utilizing
the complete regression equation of the multivariate
model to predict mortality risk, was more stable at the
extremes of risk and had greater predictive accuracy [26].
However, we have shown that the prognostic performance
of the logistic EuroSCORE is poor in patients undergoing
AVR, and progressively worsens as risk increases. Similar
findings were reported by others in octogenarians under-
going valve operations [21] and in patients undergoing
coronary artery bypass graft surgery [32].
It has been shown that subtle inter-institutional differ-
ences in the definitions of variables, in the sensitivity of
risk factor screening tools, and in the potential presence of
various degrees of interdependence and collinearity
among covariates assumed to be independent may pro-
foundly affect the performance of a risk prediction model
such as the EuroSCORE [33]. However, these influences
are likely to be minor in our study given the availability of
a nuanced dataset at our institution in which patient
information on over 200 variables was prospectively col-
lected at the time of surgery with minimal retrospective
chart review, allowing us to adhere to the EuroSCORE def-
initions of variables as faithfully as possible and to score
patients accurately. In no instance was risk factor status
imputed secondary to incomplete or missing data fields.
Recent reports suggest that 30–40% of patients in which
AVR is indicated are denied surgical treatment, mostly sec-
ondary to advanced age and left ventricular dysfunction
[34,35]. Less invasive, catheter-based approaches to
relieving the obstruction to left ventricular outflow in
severe AS were developed in an attempt to target the sub-
set of patients who were not felt to be candidates for con-
ventional open AVR in order to potentially favorably alter
their dismal prognosis. Initially, transcatheter AVR was
offered to patients on compassionate grounds and was
largely reserved for moribund patients with end-stage AS
in whom risk factors were felt to be prohibitive for tradi-
tional surgery. As experience with transcatheter aortic
valve implantation increased with attendant improve-
ments in feasibility, safety, and efficacy profiles, patient
selection criteria were expanded and investigators are
increasingly relying on EuroSCORE to determine eligibil-
ity for catheter-based intervention on the aortic valve.
Recent reports evaluating retrograde transfemoral and
transapical aortic valve implantation have included
patients with mean logistic EuroSCORE 11–35 [6-8,10-
13]. In these studies, 30-day mortality rates range from 7
to 22% and the incidence of stroke ranges from 0 to 10%.
However, these studies are limited by small numbers of
patients and lack long-term data. In our study, the inci-
dence of early stroke was 5.1% in the subgroup of patients
with logistic EuroSCORE > 20; 30-day mortality in this
high-risk group of patients was 11.4%. Furthermore, five-
year survival was acceptable at nearly 60% despite a pre-
dicted operative mortality of approximately 40% in this
cohort of patients. Taken further, this very same cohort of
patients could have been potentially denied life-prolong-
ing operation under current EuroSCORE criteria. How-
ever, this study is not a comparison of the effectiveness of
conventional AVR and transcatheter aortic valve implan-
tation, nor is it an analysis of the relative merits of one
approach over the other. Importantly, our study does not
attempt to question the value of important novel
approaches to valvular heart disease but questions the
validity of using EuroSCORE as a predictive model for
high-risk patients with severe AS and suggests that caution
should be exercised when using the EuroSCORE risk
model to make important management decisions in this
complex patient population. This is particularly impor-
tant when one attempts to make inter-institutional com-
parisons, compare individual surgeons with different case
mixes, predict risk for any single individual patient, or
determine patient eligibility for surgery.
Study limitations
These data reflect the experience of a single center which
may limit the study's generalizability. However, our surgi-
cal approach to AVR is not likely to be substantially differ-
ent from the practice at other centers. Also, our overall 30-
day mortality of 4.6% following AVR and 11.4% in high-
risk patients is within the lower range of post-AVR mortal-
ity data reported by the Society of Thoracic Surgeons who
have examined more than 40,000 patients [36].
Another important limitation relates to the lack of data on
the larger population of patients with severe aortic steno-
sis who are never presented to our multidisciplinary peer
review conference, either because of an a priori judgment
made by the health care provider as to a patient's lack ofJournal of Cardiothoracic Surgery 2009, 4:32 http://www.cardiothoracicsurgery.org/content/4/1/32
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"operability," or a patient's own refusal to be considered
for surgery. Therefore, we cannot comment on this wider
denominator of untreated patients in the community.
However, previous work from our group showed that
88.9% of patients presented to conference eventually
undergo operation [23], which is higher than most pub-
lished reports and is consistent with the existence of a
more "aggressive" approach at our institution in accepting
patients for surgery. Therefore, it is unlikely that a mean-
ingful selection bias is present in this study such that truly
high-risk patients are systematically turned away from sur-
gery, and this limitation does not weaken our data or the
study's validity in reporting the outcome of 237 consecu-
tive high-risk patients with severe aortic stenosis and a
EuroSCORE of greater than 20. Moreover, in a recent
study of patients refused for AVR, mostly by cardiac sur-
geons, no differences in EuroSCORE were identified
between those patients who underwent operation com-
pared to those who did not [37].
Conclusion
In our consecutive series of patients with severe AS under-
going AVR, we found that the logistic EuroSCORE was not
an accurate risk assessment tool in all categories of risk but
especially in high-risk patients. Therefore, this predictive
model should not be used to determine procedural risk in
patients with severe AS. Furthermore, the utilization of the
logistic EuroSCORE in the assessment of operability in
patients with severe AS may not be appropriate. More
accurate risk prediction models are needed for risk-strati-
fying patients with severe AS.
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